Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Enlivex Therapeutics Ltd
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
February 07, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
January 17, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
December 20, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
September 11, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 07, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19
August 02, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
July 31, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
June 26, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex to Present at the 2023 Jefferies Healthcare Conference
June 06, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy
May 31, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy
May 08, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy
April 19, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Appoints Andrew Singer to its Board of Directors
April 17, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates
April 04, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors
April 03, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers
March 20, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Receives Clearance From Spanish Agency of Medicines and Medical Devices For Treatment of Patients with Advanced Solid Malignancies in the Ongoing Allocetra Phase I/II Clinical Trial
February 23, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS
February 15, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors
January 25, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium
January 04, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update
December 05, 2022
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
November 28, 2022
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
November 15, 2022
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex to Present at the 37th Annual Meeting of the Society For Immunotherapy Of Cancer
November 10, 2022
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex to Present at the 4th Macrophage-Directed Therapies Summit
October 03, 2022
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.